rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy

Detalhes bibliográficos
Autor(a) principal: Santos-Filho, Norival A. [UNESP]
Data de Publicação: 2016
Outros Autores: Sousa, Tiago S., Boldrini-Franca, Johara, Santos-Silva, Ludier K., Menaldo, Danilo L., Henrique-Silva, Flavio, Cintra, Adelia C. O., Laure, Helen J., Mamede, Carla C. N., Oliveira, Fabio, Riul, Thalita B., Dias-Baruffi, Marcelo, Rosa, Jose C., Sampaio, Suely V.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1016/j.toxicon.2016.10.018
http://hdl.handle.net/11449/162275
Resumo: Phospholipase A(2) inhibitors (PLIs) are important targets in the search and development of new drugs. This study aimed at evaluating the potential of an alpha-type phospholipase A(2) inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake in its recombinant form (rBaltMIP) to complement the conventional antivenom therapy. Biochemical experiments showed that rBaltMIP presented pl 5.8 and molecular masses of similar to 21 kDa by SDS-PAGE and 19.57 kDa by MALDI/TOF MS. After tryptic peptides sequencing, the results were compared with other PLIs available in databases, showing 100% identity between rBaltMIP and its native inhibitor BaItMIP and from 92% to 96% identity with other inhibitors. Myotoxic activities of BthTX-1 and BthTX-II toxins were measured via plasma CI(levels, showing myotoxic effective concentrations (EC50) of 0.1256 p.g/ 1, and 0.6183 mu g/mu L, respectively. rBaltMIP neutralized the myotoxicity caused by these two toxins up to 65%, without promoting primary antibody response against itself. Nevertheless, this recombinant PLI was immunogenic when standard immunization protocol with Freud's adjuvant was used. In paw edema assays, EC50 of 0.02581 mu g/mu L and 0.02810 mu g/mu L, respectively, were observed with edema reductions of up to 40% by rBaltMIP, suggesting its use as an additional antivenom. In addition, myotoxicity neutralization experiments with the myotoxin BthTX-I showed that rBaltMIP was more effective in inhibiting muscle damage than the conventional anti venom. Thus, considering the severity of envenomations due to Bothrops alternatus (Rhinocerophis alternatus) and the low neutralization of their local effects (such as myotoxicity) by the current anti venoms, rBaltMIP is a promising molecule for the development of novel therapeutic strategies for clinical applications. (C) 2016 Elsevier Ltd. All rights reserved.
id UNSP_3a0eba6bb443c9eb8ef6e84b512ebf5e
oai_identifier_str oai:repositorio.unesp.br:11449/162275
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapyBothrops alternatusrBaltMIPPhospholipase A(2) inhibitoralpha PLIPhospholipase A(2) inhibitors (PLIs) are important targets in the search and development of new drugs. This study aimed at evaluating the potential of an alpha-type phospholipase A(2) inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake in its recombinant form (rBaltMIP) to complement the conventional antivenom therapy. Biochemical experiments showed that rBaltMIP presented pl 5.8 and molecular masses of similar to 21 kDa by SDS-PAGE and 19.57 kDa by MALDI/TOF MS. After tryptic peptides sequencing, the results were compared with other PLIs available in databases, showing 100% identity between rBaltMIP and its native inhibitor BaItMIP and from 92% to 96% identity with other inhibitors. Myotoxic activities of BthTX-1 and BthTX-II toxins were measured via plasma CI(levels, showing myotoxic effective concentrations (EC50) of 0.1256 p.g/ 1, and 0.6183 mu g/mu L, respectively. rBaltMIP neutralized the myotoxicity caused by these two toxins up to 65%, without promoting primary antibody response against itself. Nevertheless, this recombinant PLI was immunogenic when standard immunization protocol with Freud's adjuvant was used. In paw edema assays, EC50 of 0.02581 mu g/mu L and 0.02810 mu g/mu L, respectively, were observed with edema reductions of up to 40% by rBaltMIP, suggesting its use as an additional antivenom. In addition, myotoxicity neutralization experiments with the myotoxin BthTX-I showed that rBaltMIP was more effective in inhibiting muscle damage than the conventional anti venom. Thus, considering the severity of envenomations due to Bothrops alternatus (Rhinocerophis alternatus) and the low neutralization of their local effects (such as myotoxicity) by the current anti venoms, rBaltMIP is a promising molecule for the development of novel therapeutic strategies for clinical applications. (C) 2016 Elsevier Ltd. All rights reserved.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Nucleo de Apoio a Pesquisa em Doencas Inflamatorias (NAPDIN)Univ Sao Paulo, FCFRP, Dept Anal Clin Toxicol & Bromatol, Ribeirao Preto, SP, BrazilUniv Fed Sao Carlos, UFScar, Dept Genet & Evolucao, Sao Carlos, SP, BrazilUniv Fed Uberlandia, Inst Ciencias Biomed, Dept Ciencias Fisiol, Uberlandia, MG, BrazilUniv Estadual Paulista, Inst Quim, Dept Bioquim & Tecnol Quim, Araraquara, SP, BrazilUniv Sao Paulo, FMRP, Dept Biol Celular & Mol & Bioagentes Patogen, Ribeirao Preto, SP, BrazilUniv Estadual Paulista, Inst Quim, Dept Bioquim & Tecnol Quim, Araraquara, SP, BrazilFAPESP: 2008/10760-4FAPESP: 2011/23236-4CNPq: 467646/2014-7CNPq: 476932/2012-2Nucleo de Apoio a Pesquisa em Doencas Inflamatorias (NAPDIN): 11.1.21625.01.0Elsevier B.V.Universidade de São Paulo (USP)Universidade Federal de São Carlos (UFSCar)Universidade Federal de Uberlândia (UFU)Universidade Estadual Paulista (Unesp)Santos-Filho, Norival A. [UNESP]Sousa, Tiago S.Boldrini-Franca, JoharaSantos-Silva, Ludier K.Menaldo, Danilo L.Henrique-Silva, FlavioCintra, Adelia C. O.Laure, Helen J.Mamede, Carla C. N.Oliveira, FabioRiul, Thalita B.Dias-Baruffi, MarceloRosa, Jose C.Sampaio, Suely V.2018-11-26T17:15:26Z2018-11-26T17:15:26Z2016-12-15info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article53-62application/pdfhttp://dx.doi.org/10.1016/j.toxicon.2016.10.018Toxicon. Oxford: Pergamon-elsevier Science Ltd, v. 124, p. 53-62, 2016.0041-0101http://hdl.handle.net/11449/16227510.1016/j.toxicon.2016.10.018WOS:000390518600007WOS000390518600007.pdfWeb of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengToxicon0,692info:eu-repo/semantics/openAccess2023-11-13T06:16:16Zoai:repositorio.unesp.br:11449/162275Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T17:36:04.356735Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
title rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
spellingShingle rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
Santos-Filho, Norival A. [UNESP]
Bothrops alternatus
rBaltMIP
Phospholipase A(2) inhibitor
alpha PLI
title_short rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
title_full rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
title_fullStr rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
title_full_unstemmed rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
title_sort rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
author Santos-Filho, Norival A. [UNESP]
author_facet Santos-Filho, Norival A. [UNESP]
Sousa, Tiago S.
Boldrini-Franca, Johara
Santos-Silva, Ludier K.
Menaldo, Danilo L.
Henrique-Silva, Flavio
Cintra, Adelia C. O.
Laure, Helen J.
Mamede, Carla C. N.
Oliveira, Fabio
Riul, Thalita B.
Dias-Baruffi, Marcelo
Rosa, Jose C.
Sampaio, Suely V.
author_role author
author2 Sousa, Tiago S.
Boldrini-Franca, Johara
Santos-Silva, Ludier K.
Menaldo, Danilo L.
Henrique-Silva, Flavio
Cintra, Adelia C. O.
Laure, Helen J.
Mamede, Carla C. N.
Oliveira, Fabio
Riul, Thalita B.
Dias-Baruffi, Marcelo
Rosa, Jose C.
Sampaio, Suely V.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade de São Paulo (USP)
Universidade Federal de São Carlos (UFSCar)
Universidade Federal de Uberlândia (UFU)
Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Santos-Filho, Norival A. [UNESP]
Sousa, Tiago S.
Boldrini-Franca, Johara
Santos-Silva, Ludier K.
Menaldo, Danilo L.
Henrique-Silva, Flavio
Cintra, Adelia C. O.
Laure, Helen J.
Mamede, Carla C. N.
Oliveira, Fabio
Riul, Thalita B.
Dias-Baruffi, Marcelo
Rosa, Jose C.
Sampaio, Suely V.
dc.subject.por.fl_str_mv Bothrops alternatus
rBaltMIP
Phospholipase A(2) inhibitor
alpha PLI
topic Bothrops alternatus
rBaltMIP
Phospholipase A(2) inhibitor
alpha PLI
description Phospholipase A(2) inhibitors (PLIs) are important targets in the search and development of new drugs. This study aimed at evaluating the potential of an alpha-type phospholipase A(2) inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake in its recombinant form (rBaltMIP) to complement the conventional antivenom therapy. Biochemical experiments showed that rBaltMIP presented pl 5.8 and molecular masses of similar to 21 kDa by SDS-PAGE and 19.57 kDa by MALDI/TOF MS. After tryptic peptides sequencing, the results were compared with other PLIs available in databases, showing 100% identity between rBaltMIP and its native inhibitor BaItMIP and from 92% to 96% identity with other inhibitors. Myotoxic activities of BthTX-1 and BthTX-II toxins were measured via plasma CI(levels, showing myotoxic effective concentrations (EC50) of 0.1256 p.g/ 1, and 0.6183 mu g/mu L, respectively. rBaltMIP neutralized the myotoxicity caused by these two toxins up to 65%, without promoting primary antibody response against itself. Nevertheless, this recombinant PLI was immunogenic when standard immunization protocol with Freud's adjuvant was used. In paw edema assays, EC50 of 0.02581 mu g/mu L and 0.02810 mu g/mu L, respectively, were observed with edema reductions of up to 40% by rBaltMIP, suggesting its use as an additional antivenom. In addition, myotoxicity neutralization experiments with the myotoxin BthTX-I showed that rBaltMIP was more effective in inhibiting muscle damage than the conventional anti venom. Thus, considering the severity of envenomations due to Bothrops alternatus (Rhinocerophis alternatus) and the low neutralization of their local effects (such as myotoxicity) by the current anti venoms, rBaltMIP is a promising molecule for the development of novel therapeutic strategies for clinical applications. (C) 2016 Elsevier Ltd. All rights reserved.
publishDate 2016
dc.date.none.fl_str_mv 2016-12-15
2018-11-26T17:15:26Z
2018-11-26T17:15:26Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1016/j.toxicon.2016.10.018
Toxicon. Oxford: Pergamon-elsevier Science Ltd, v. 124, p. 53-62, 2016.
0041-0101
http://hdl.handle.net/11449/162275
10.1016/j.toxicon.2016.10.018
WOS:000390518600007
WOS000390518600007.pdf
url http://dx.doi.org/10.1016/j.toxicon.2016.10.018
http://hdl.handle.net/11449/162275
identifier_str_mv Toxicon. Oxford: Pergamon-elsevier Science Ltd, v. 124, p. 53-62, 2016.
0041-0101
10.1016/j.toxicon.2016.10.018
WOS:000390518600007
WOS000390518600007.pdf
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Toxicon
0,692
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 53-62
application/pdf
dc.publisher.none.fl_str_mv Elsevier B.V.
publisher.none.fl_str_mv Elsevier B.V.
dc.source.none.fl_str_mv Web of Science
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128834082439168